For a patient after percutaneous coronary intervention, should I use apixaban or rivaroxaban, and what are the recommended dosing and antiplatelet therapy regimens?

Anticoagulation Strategy Post-PCI: Apixaban vs Rivaroxaban

Both apixaban and rivaroxaban are acceptable DOACs for patients after PCI, but the choice depends on your indication for anticoagulation (atrial fibrillation vs VTE) and requires specific dosing adjustments that differ between these agents.

For Atrial Fibrillation Post-PCI

Rivaroxaban Dosing (AF indication)

Use rivaroxaban 15 mg once daily (not the standard 20 mg AF dose) while on concomitant antiplatelet therapy if CrCl >50 mL/min, or 10 mg daily if CrCl 30-50 mL/min 1. This reduced dose is based on the PIONEER AF-PCI trial and is specifically for use with P2Y12 inhibitors 2. Critical: Once you stop antiplatelet therapy, you must increase rivaroxaban to the full FDA-approved AF dose (20 mg daily, or 15 mg if renally adjusted) 1.

Apixaban Dosing (AF indication)

Use standard FDA-approved AF doses: 5 mg twice daily, or 2.5 mg twice daily if patient meets ≥2 of these criteria: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 1, 3. Unlike rivaroxaban, apixaban does not require dose reduction when combined with antiplatelet therapy.

Antiplatelet Regimen with Either DOAC (AF patients)

Default strategy (most patients):

• Discharge: DOAC + clopidogrel (dual therapy) - stop aspirin at discharge 1, 4
• Duration: Continue clopidogrel for 6 months (stable ischemic heart disease) or 12 months (ACS presentation) 1
• After antiplatelet cessation: Continue DOAC monotherapy indefinitely 4

High thrombotic risk/low bleeding risk patients only:

• May add aspirin 81 mg daily for up to 30 days post-PCI (triple therapy), then transition to dual therapy 1, 4

For VTE Post-PCI

Initial Treatment Phase (if within first 3 months of VTE)

Apixaban: 10 mg twice daily for 7 days, then 5 mg twice daily 1, 3

Rivaroxaban: 15 mg twice daily for 21 days, then 20 mg daily 1

Complete the initiation dose regimen first, then combine with antiplatelet therapy 1. The VTE dose must be maintained (not the reduced AF dose) 1.

Antiplatelet Strategy with VTE

• <6 months post-PCI: Stop aspirin, continue clopidogrel + full-dose DOAC 1
• 6-12 months post-PCI: Continue either aspirin or clopidogrel + DOAC until 1 year 1
• >12 months post-PCI: DOAC monotherapy 1

Extended VTE Prevention (>6 months after initial VTE)

After completing initial treatment, reduced-dose options become available:

• Apixaban: 2.5 mg twice daily 1
• Rivaroxaban: 10 mg daily 1

Key Practical Differences

Apixaban advantages:

• No dose adjustment needed when combined with antiplatelet therapy
• Twice-daily dosing may improve adherence through routine
• Recent VTE data suggests lower bleeding risk than rivaroxaban 5
• Simpler dosing transitions

Rivaroxaban considerations:

• Requires specific reduced dosing (15 mg) during antiplatelet therapy for AF
• Must remember to uptitrate after stopping antiplatelet therapy
• Once-daily dosing after initial VTE phase
• Has longer initiation phase for VTE (21 days vs 7 days)

Critical Timing Points

Resume anticoagulation: Within 24 hours post-PCI in most patients (can be same evening if low bleeding risk) 1

Proton pump inhibitor: Mandatory for all patients on combination therapy 1

Clopidogrel is the preferred P2Y12 inhibitor over ticagrelor or prasugrel due to lower bleeding risk 1, 4

Common Pitfalls to Avoid

1. Using rivaroxaban 20 mg daily with antiplatelet therapy in AF patients - this is incorrect; must use 15 mg 1
2. Forgetting to uptitrate rivaroxaban after stopping antiplatelet therapy - the 15 mg dose is insufficient for stroke prevention alone 1
3. Continuing triple therapy beyond 30 days - increases bleeding without additional benefit in most patients 1, 4
4. Using prasugrel or ticagrelor instead of clopidogrel - significantly increases bleeding risk 1
5. Dose-reducing apixaban when adding antiplatelet therapy - not indicated unless patient meets the specific AF dose reduction criteria 1